| Added by | ircm doc |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery |
| Creator | Houvenaeghel et al. |
| Author | Gilles Houvenaeghel |
| Author | Jean-Marc Classe |
| Author | Marie-Pierre Chauvet |
| Author | Pierre-Emmanuel Colombo |
| Author | Eva Jouve |
| Author | Fabien Reyal |
| Author | Emile Daraï |
| Author | Roman Rouzier |
| Author | Christelle Faure-Virelizier |
| Author | Pierre Gimbergues |
| Author | Charles Coutant |
| Author | Chafika Mazouni |
| Author | Anne-Sophie Azuar |
| Author | Marc Martino |
| Author | Catherine Bouteille |
| Author | Monique Cohen |
| Author | Alexandre de Nonneville |
| Abstract | Background: Despite early diagnosis, approximately 20% of patients with ER-positive and HER2-negative breast cancer (BC) will experience disease recurrence. Improved survival has been reported with adjuvant treatment combining cyclin-dependent kinase 4/6 inhibitors with endocrine therapy, in high-risk patients with ER-positive and HER2-negative BC, regardless of age. Older patients have higher rates of ER-positive/HER2-negative BC than younger patients. Methods: In this real-world data analysis, MonarchE and NataLEE high-risk patients accounted for 9.5% and 33% of patients undergoing upfront surgery, respectively. Significantly higher eligibility rates were observed in patients who underwent a mastectomy, >70 years and ?40 years for adjuvant abemaciclib and ribociclib, and in patients >80 years for ribociclib. Results: Eligibility rates in patients ?40 years and >80 years who underwent mastectomy were 27.8% and 24.7% for abemaciclib, respectively, and 56.6% and 65.2% for ribociclib, respectively. A higher discontinuation rate for abemaciclib was reported in patients aged ?65 years and it can be assumed that discontinuation rates may increase in even older patients. Conclusions: If the results of the NataLEE trial translate into clinical practice, the number of patients potentially eligible for adjuvant CDK4/6 inhibitors may increase, especially in the elderly population. |
| Publication | Cancers |
| Volume | 16 |
| Issue | 19 |
| Pages | 3317 |
| Date | 2024-09-27 |
| Journal Abbr | Cancers (Basel) |
| Language | eng |
| DOI | 10.3390/cancers16193317 |
| ISSN | 2072-6694 |
| Library Catalog | PubMed |
| Extra | PMID: 39409937 PMCID: PMC11475696 |
| Tags | breast cancer, clinic, sentinel lymph nodes |
| Date Added | 2025/01/16 - 12:00:03 |
| Date Modified | 2025/01/16 - 12:01:41 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
